LifeArc

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 14
Average round size
info
The average size of a deal this fund participated in
$31M
Portfolio companies 12
Rounds per year 0.48
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.14
Exits 1
Key employees 1

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Biopharma
Summary

LifeArc appeared to be the Corporate Investor, which was created in 1992. The main department of described Corporate Investor is located in the London. The fund was located in Europe if to be more exact in United Kingdom.

Considering the real fund results, this Corporate Investor is 30 percentage points more often commits exit comparing to other organizations. The fund is generally included in less than 2 deals every year. Opposing the other organizations, this LifeArc works on 4 percentage points less the average amount of lead investments. The important activity for fund was in 2019. The usual things for fund are deals in the range of 50 - 100 millions dollars.

Among the most successful fund investment fields, there are Biopharma, Therapeutics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline AMR Centre, Caldan Therapeutics For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the LifeArc, startups are often financed by Scottish Investment Bank, Scottish Enterprise, Science Ventures. The meaningful sponsors for the fund in investment in the same round are Pfizer Venture Investments, OrbiMed, SciTech. In the next rounds fund is usually obtained by Samsara BioCapital, Pfizer Venture Investments, Perceptive Advisors.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of LifeArc:
Typical Co-investors
LifeArc is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after LifeArc:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Arch Chemicals Connecticut, Norwalk, United States
Bitlink Capital -
Cineplex Entertainment Canada, Ontario, Toronto
Congress Avenue Ventures -
Fractal -
GO Ventures -
Gold Mountains Asset Management Co. Ltd China, Hong Kong, Kowloon
Jupiter Partners New York, New York, United States
KES 7 Capital Canada, Ontario, Toronto
Middleland Capital District of Columbia, United States, Washington
Qinhuangdao Aosheng Investment China, Hebei, Qinhuangdao
ReBoost Japan, Tokyo
Tethys BioScience California, Emeryville, United States
TFI International California, Los Angeles, United States
The Judd Leighton Foundation -
Thrive Agtech Accelerator California, Los Gatos, United States
Unlock Venture Partners Seattle, United States, Washington
World Wrestling Entertainment Connecticut, Stamford, United States
Zhongtai Investment -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

AviadoBio

$80M02 Dec 2021 London, England, United Kingdom

Closed Loop Medicine

Health Care
Pharmaceutical
Therapeutics
$17M03 Nov 2021 London, England, United Kingdom

Eliem Therapeutics

Biotechnology
Health Care
Pharmaceutical
$60M24 May 2021 Washington, United States

Cumulus Neuroscience

$8M04 May 2021 Belfast, Northern Ireland, United Kingdom

DJS Antibodies

Biotechnology
Health Care
$8M22 Dec 2020 Oxford, England, United Kingdom

BrainWaveBank

Clinical Trials
Health Care
Health Diagnostics
Medical Device
mHealth
Neuroscience
Pharmaceutical
$8M08 Dec 2020 Belfast, Northern Ireland, United Kingdom

Biopharma
Biotechnology
Pharmaceutical
$1M03 Jun 2020 Sweden, Västra Götaland County, Sweden

PolyProx

Biotechnology
Health Care
Therapeutics
$1M02 Mar 2020 Cambridge, Cambridgeshire, United Kingdom

Ikarovec

Biotechnology
Health Care
Life Science
$3M05 Feb 2020 United Kingdom, England
News
Eliem Therapeutics Announces $60 Million Series B Financing

– Eliem Therapeutics, Inc. announced the closing of a $60m Series B financing.
– The round was led by ICG and included participation from Access Biotechnology, Samlyn Capital, Acorn Bioventures and LifeArc.
– Eliem plans to use the proceeds to advance its two lead clinical-stage product candidates, ETX-810 and ETX-155, through topline data across four different indications in patients with chronic pain, depressive disorders, and epilepsy, as well as to advance its two preclinical-stage programs to selection of clinical development candidates.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent LifeArc?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: